MPLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MPLX is not a strong buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has some supportive income/quality characteristics, but the current technical setup is weak and the latest analyst changes are mixed-to-slightly negative. Since the user is impatient and does not want to wait for a better entry, I would not buy aggressively at this price; the better call is to hold and wait for a cleaner trend or a lower entry.
The technical picture is bearish in the near term. MACD histogram is negative and worsening, RSI_6 is 14.52, which shows the stock is oversold, and moving averages are stacked bearishly with SMA_200 > SMA_20 > SMA_5. That means the broader trend is still down even though short-term selling may be extended. Price closed at 56.8, slightly below the prior close of 57.16. The provided pattern-based trend estimate also points to modest near-term weakness: +1.27% next day, then -1.99% next week and -5.02% next month.
No news in the last week, so there is no fresh event-driven catalyst. Positives come mainly from the company’s long-term income appeal, the analyst community still having several Overweight/Buy ratings, and bullish options positioning. Barclays described an "increasingly constructive backdrop" for U.S. crude production, and MPLX has reiterated plans to grow distributions by 12.5% annually for 2026/2027.
The recent price target trend is slightly softer, with multiple analysts trimming targets. The stock is also showing weak technical momentum and no recent news catalyst. Market trend is not helping either, with the S&P 500 slightly down on the day. For a Beginner focused on long-term investing, the current chart weakness and lack of a fresh catalyst argue against buying immediately.
No usable latest-quarter financial snapshot was provided because of an error, so I cannot assess the most recent quarter directly. The only financial guidance available in the data is management's distribution growth plan of 12.5% annually for 2026/2027, which supports a stable long-term income thesis, but there is no current-quarter revenue/earnings growth data to confirm acceleration.
Analyst sentiment remains mixed but still moderately constructive. Morgan Stanley cut the target to $60 and kept Equal Weight. Barclays raised then later lowered targets to $59 and $58 while keeping Overweight. Wells Fargo cut its target to $61 but kept Overweight, citing softer segment margins and reduced buyback assumptions. Goldman Sachs is the most bullish in the recent set, raising its target to $63 and keeping Buy. Overall, Wall Street still has a positive bias, but the trend in price targets has been downward over the last few updates, which is a mild negative.
